Redmile Group, LLC's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Dec 28, 2023
- Accession no.
- 0001104659-23-130203
- Filed
- Dec 28, 2023, 9:30 PM ET
- Trade date
- Dec 26, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $166.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Redmile Group, LLCCIK 0001425738 | Director, 10% Owner |
| Green JeremyCIK 0001650527 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 26, 2023 | Common Stock | JOtherDisposed | −1,655,370 | $3.72 | −$6,157,976.4 | 13,135,758 | Indirect | |
| Dec 26, 2023 | Common Stock | JOtherAcquired | +1,655,370 | $3.72 | +$6,157,976.4 | 13,135,758 | Indirect | |
| Dec 26, 2023 | Common Stock | PPurchaseAcquired | +44,630 | $3.72 | +$166,023.6 | 13,180,388 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Mr. Michael Lee, a member of the board of directors of the Issuer and a managing director of Redmile, was elected to the board of the Issuer as a representative of Redmile and its affiliates. As a result, the Reporting Persons are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.